No Data
No Data
Guangzhou Baiyunshan Pharmaceutical Gets License to Expand Unit's Drug Production License
Hong Kong stock announcement | Two national-level specialized, special and new "little giant" enterprises added to circ
Wuxi AppTec (02359) plans to repurchase 1 billion yuan of A shares to further maintain the company's value and shareholder rights; Baiyunshan (00874): glyceryl trinitrate injection has passed the generic drug quality and efficacy consistency evaluation.
Baiyunshan Pharma Gets China Supplemental Drug Nod for Nitroglycerin Injection for Heart Problems
Baiyunshan (600332.SH): Nitroglycerin Injection Passes Generic Drug Consistency Evaluation.
On September 10th, Baiyunshan (600332.SH) announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., has received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration. The Nitroglycerin Injection (specification: 1ml:5mg) has passed the evaluation of generic drug quality and therapeutic efficacy consistency. Nitroglycerin Injection can be used for blood pressure control in patients during cardiac or surgical procedures, or for the treatment of unstable angina and concealed congestive heart failure.
Baiyunshan ph (00874) received the "Pharmaceutical Production License" approved and issued by the Guangdong Pharmaceutical Supervision Administration.
Baiyunshan (00874) announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (also known as...
Baiyunshan (00874) dropped 25.50%, currently trading at 17.360 yuan, hitting a new 52-week low.
As of 11:43, Baiyunshan (00874) fell 25.50% compared to the previous closing price and is now reported at 17.360 yuan, hitting a 52-week low. The trading volume is 0.926 million shares, with a turnover of 16.0908 million Hong Kong dollars.
No Data
No Data